Sign in

You're signed outSign in or to get full access.

IP

INOVIO PHARMACEUTICALS, INC. (INO)·Q3 2025 Earnings Summary

Executive Summary

  • Completed the rolling BLA for INO-3107, requested priority review; management expects FDA file acceptance by year-end 2025 and a potential mid-2026 PDUFA if priority review is granted .
  • Operating discipline continued: Total operating expenses fell 22% YoY to $21.2M; loss from operations improved to $21.2M vs $27.3M in Q3 2024, but GAAP net loss widened to $45.5M due to a $22.5M non-cash warrant fair value loss .
  • Liquidity: Cash, cash equivalents and short-term investments stood at $50.8M; company guides runway into Q2 2026 (ex any additional capital), with Q4 2025 net operational cash burn ~$22M .
  • Additional liquidity: INOVIO priced a $25M common stock offering on Nov 11, 2025, adding capital flexibility ahead of potential 2026 launch .
  • Near-term stock catalysts: formal FDA BLA acceptance, clarity on priority review timeline, confirmatory trial initiation during review, and ongoing competitive differentiation vs Papzimeos (MRD surgery requirement) .

What Went Well and What Went Wrong

What Went Well

  • Rolling BLA submission completed; management reiterated potential mid-2026 approval timeline with priority review as a key gating factor. “We’ve completed the rolling submission of our BLA… potential PDUFA date in mid-2026 if request for priority review granted” .
  • Operating discipline: OpEx dropped 22% YoY and loss from operations improved materially; CFO emphasized focus on resourcing INO-3107 launch preparation .
  • Platform validation: DMAb proof-of-concept published in Nature Medicine showed durable in vivo expression, no ADA across ~1,000 samples, and functional activity—bolstering long-term pipeline credibility .

What Went Wrong

  • GAAP net loss increased to $45.5M, driven by a $22.5M non-cash warrant fair value adjustment that can create reported volatility independent of operations .
  • Cash declined to $50.8M vs $94.1M at 12/31/2024 prior to the subsequent equity raise, implying tight pre-commercial funding conditions even as runway extends into Q2 2026 .
  • Zero revenue and continued dependence on capital markets underscores execution risk around regulatory timelines and commercialization readiness ahead of mid-2026 .

Financial Results

Income Statement Trends (older → newer)

MetricQ3 2024Q1 2025Q2 2025Q3 2025
Revenue from collaborative arrangements ($USD)$0 $65,343 $0 $0
Research & Development ($USD)$18,733,584 $16,090,902 $14,521,407 $13,333,329
General & Administrative ($USD)$8,613,895 $9,024,970 $8,563,112 $7,877,126
Total Operating Expenses ($USD)$27,347,479 $25,115,872 $23,084,519 $21,210,455
Loss from Operations ($USD)$(27,347,479) $(25,050,529) $(23,084,519) $(21,210,455)
Net Loss ($USD)$(25,165,478) $(19,694,697) $(23,519,412) $(45,496,672)
Diluted EPS ($)$(0.89) $(0.51) $(0.61) $(0.87)

Note: Traditional margins are not meaningful given de minimis/zero revenue .

Balance Sheet Snapshot (older → newer)

MetricDec 31, 2024Sep 30, 2025
Cash & Cash Equivalents ($USD)$65,813,297 $36,567,420
Short-term Investments ($USD)$28,300,232 $14,235,770
Common Stock Warrant Liabilities ($USD)$13,255,188 $50,384,043
Total Stockholders’ Equity ($USD)$68,503,795 $(7,719,977)

Results vs S&P Global Consensus (estimates marked with *)

MetricQ3 2025 ActualQ3 2025 Consensus*Q4 2025 Consensus*
Primary EPS ($)$(0.87) $(0.42333)*$(0.355)*
Revenue ($USD)$0 $0.00*$0.00*
EBITDA ($USD)———
Target Price ($)—$7.63333*$7.63333*

Values retrieved from S&P Global.

KPIs and Operating Items

KPIQ3 2025
Loss from operations per share ($)$(0.41)
Change in fair value of warrant liabilities ($USD)$(22,515,730)
Shares outstanding (basic, period-end)53.6M common; 94.5M fully diluted
Cash runway guidanceInto Q2 2026; Q4 2025 net operational cash burn ~$22M
Subsequent financingPriced $25M equity offering on Nov 11, 2025

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash runwayQ1 2025Into Q1 2026 ——
Cash runwayQ2 2025Into Q2 2026 (includes July 2025 ~$22.5M net proceeds) —Raised vs Q1
Cash runwayQ3 2025—Into Q2 2026; Q4 2025 net operational cash burn ~$22M Maintained vs Q2; added burn detail
BLA timeline (INO-3107)Q1 2025Begin rolling mid-2025; complete in 2H25; FDA acceptance by YE 2025; potential mid-2026 PDUFA with priority review ——
BLA timeline (INO-3107)Q2 2025On track; DV complete; rolling requested; priority review planned —Maintained progress
BLA timeline (INO-3107)Q3 2025—Rolling BLA completed; requested priority review; expect file acceptance by YE 2025; potential mid-2026 PDUFA Advanced to submission completed

Earnings Call Themes & Trends

TopicPrevious Mentions (Q1 & Q2 2025)Current Period (Q3 2025)Trend
Regulatory pathway (BLA, priority review)Q1: plan for rolling mid-2025; Q2: DV complete, rolling requested Rolling BLA completed; expect acceptance by YE; potential mid-2026 PDUFA Progressing to review stage
Confirmatory trial designQ2: randomized placebo-controlled trial targeted; ~20 U.S. sites Aligning with FDA (Type D meeting); enroll a patient prior to approval; flexibility given changing landscape Design being optimized
Commercial preparationQ2: advancing market research and operational build-out Pricing strategy, partner contracts, segmentation, field teams preparation Accelerating readiness
Competitor dynamics (Papzimeos MRD surgeries)Not emphasized earlierDifferentiation narrative: MRD surgeries during dosing window counted differently; patient-centric regimen Differentiation sharpening
Next-gen platforms (DMAb, DPROT)Q1/Q2: interim DMAb data, platform overview Nature Medicine publication; preparing hemophilia A factor VIII preclinical data Validation and pipeline optionality
Capital markets/liquidityQ2: July offering ~$22.5M net proceeds Nov 11 offering priced for ~$25M gross proceeds Additional liquidity secured

Management Commentary

  • “We have achieved our primary objective for this year, completing the rolling submission of our BLA for INO-3107… potential PDUFA date around mid-2026” — CEO Jackie Shea .
  • CMO Mike Sumner on confirmatory study and differentiation: “The agency has confirmed that we only need to have initiated the confirmatory trial and enrolled a patient prior to approval… our trial counted every surgery following the first day of treatment, in contrast to MRD surgeries not counted in competitor’s dosing window” .
  • CCO Steve Egge on launch: “We’re finalizing contracts with our specialty distributor, specialty pharmacy, and patient hub partners… plan to get out of the gate quickly if approved” .
  • CFO Peter Kies on P&L: “Operating expenses dropped… 22%… net loss increased primarily driven by a $22.5M non-cash loss on fair value adjustments related to warrant liabilities… cash runway into the second quarter of 2026” .
  • Platform: DMAb proof-of-concept “published in Nature Medicine… first demonstration that monoclonal antibodies can be durably and tolerably expressed in humans” .

Q&A Highlights

  • Competitive timing and market education: Management expects low-single-digit penetration by competitor before INO-3107 approval, with majority of prevalent opportunity remaining; fast-follower strategy planned .
  • Label and differentiation: Team anticipates a broad label and views MRD surgery requirement for Papzimeos as a key differentiator from both patient and logistics perspectives .
  • Commercial build: Field resources (MSLs, access) ahead of approval; salesforce sizing likely in line with competitor’s ~18 territories, specifics TBD .
  • Switching: No expected cross-reactivity issues for switching from Papzimeos to INO-3107; full 4-dose regimen emphasized .
  • DMAb/DPROT: Durable expression (~1 μg/mL range) observed; pipeline prioritization to proceed via partnerships/financing; factor VIII preclinical data forthcoming .

Estimates Context

  • EPS missed consensus: Q3 2025 reported EPS was $(0.87) vs S&P Global consensus of $(0.42333), driven largely by the non-cash warrant fair value loss; revenue was in line at $0 vs $0.00 .
  • Consensus composition: 6 EPS and 6 revenue estimates for Q3; Q4 2025 EPS consensus is $(0.355); target price consensus stands at $7.63 across 6 estimates. Values retrieved from S&P Global.
  • Estimate implications: The operating loss improved and OpEx trended down, but GAAP EPS volatility from warrant remeasurement suggests analysts may focus on operating metrics and cash runway rather than headline EPS .

Key Takeaways for Investors

  • Regulatory catalyst path is intact: BLA acceptance by YE 2025 and potential mid-2026 PDUFA, with confirmatory trial enrollment during review expected — critical milestones to de-risk the launch timeline .
  • Differentiation vs competitor: No MRD surgeries during dosing window in INO-3107 regimen and patient-centric office-based administration support positioning as preferred option in RRP .
  • Operating discipline: Sustained OpEx reductions and improved loss from operations highlight focus on capital efficiency heading into commercialization .
  • GAAP noise from warrants: The $22.5M non-cash warrant fair value loss materially widened EPS; investors should anchor on operating loss trajectory and cash runway .
  • Liquidity bolstered: Post-quarter $25M equity raise enhances flexibility for confirmatory and launch preparations; upcoming burn in Q4 (~$22M) is guided .
  • Platform upside optionality: DMAb Nature Medicine publication and DPROT preclinical progress expand strategic optionality for partnerships and longer-term value creation .
  • Trade setup: Near-term upside hinges on FDA acceptance and priority review confirmation; watch confirmatory trial initiation, competitor adoption pace, and commercialization build milestones .